Hodgkin’s Lymphoma Market Insight, Epidemiology And Market Forecast – 2036
The Hodgkin’s Lymphoma market across the 7MM is expected to witness significant growth during the forecast period from 2026 to 2036. The report provides a comprehensive assessment of current treatment practices, emerging therapies, market dynamics, epidemiological trends, and future growth opportunities across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. With increasing adoption of immunotherapies, targeted treatments, and innovative combination regimens, the Hodgkin’s Lymphoma treatment landscape continues to evolve, offering improved outcomes and personalized care strategies for patients.
Hodgkin’s Lymphoma Disease Understanding
Hodgkin’s Lymphoma: Overview
Hodgkin’s Lymphoma is a cancer of the lymphatic system characterized by the presence of Reed-Sternberg cells. It is one of the two primary types of lymphoma and is considered one of the most treatable forms of cancer when diagnosed early. The disease originates in B-lymphocytes, which multiply abnormally and accumulate in lymph nodes and other lymphatic tissues, impairing the body’s ability to fight infections.
The disease is broadly classified into classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Although Hodgkin’s Lymphoma can spread rapidly through the lymphatic system, advances in diagnosis and treatment have resulted in high cure rates, with more than 80% of patients achieving long-term remission and cure under current treatment approaches.
Diagnosis typically involves lymph node biopsy, immunophenotyping, blood tests, PET scans, CT scans, and staging assessments to determine disease extent and guide treatment selection.
Download the full report to explore detailed market forecasts, epidemiological trends, treatment algorithms, and competitive intelligence for Hodgkin’s Lymphoma.
Hodgkin’s Lymphoma Recent Developments
- In January 2026, MD Anderson reported a 92% complete response rate in early-stage Hodgkin lymphoma patients receiving a novel combination therapy, with 96% maintaining remission at two years.
- In January 2026, results from the SWOG S1826 trial presented at ASH 2025 confirmed superior progression-free survival with nivolumab plus AVD compared with brentuximab vedotin plus AVD in advanced-stage classical Hodgkin lymphoma.
- In December 2025, the FDA granted Priority Review to nivolumab plus AVD for untreated Stage III/IV classical Hodgkin lymphoma, with a PDUFA date of April 8, 2026.
- In December 2025, ASH 2025 highlighted the A-HIPI prognostic index as a superior risk stratification tool compared with IPS-7, while circulating tumor DNA (ctDNA) demonstrated promise for earlier disease-risk prediction.
Hodgkin’s Lymphoma Emerging Drugs
- Favezelimab/Pembrolizumab – Merck
Favezelimab is a LAG-3 inhibitor developed in combination with pembrolizumab, targeting both LAG-3 and PD-1 pathways to enhance anti-tumor immune responses. The combination is being evaluated in Phase III studies for relapsed or refractory classical Hodgkin lymphoma. Clinical data presented at ASCO 2024 demonstrated an overall response rate of 83%, with durable responses and a manageable safety profile, highlighting its potential as a future treatment option.
- TEVIMBRA (Tislelizumab) – BeiGene
TEVIMBRA is a PD-1 inhibitor designed to restore anti-tumor immune activity by blocking the PD-1/PD-L1 pathway. In August 2024, BeiGene reported completion of a Phase II trial evaluating tislelizumab in relapsed or refractory classical Hodgkin lymphoma. Additional Phase II studies are investigating its use as a first-line treatment in older Hodgkin lymphoma patients.
- Autologous CD30 CAR-T Cells – Tessa Therapeutics
Autologous CD30 CAR-T cell therapy is an innovative cellular immunotherapy targeting CD30-positive Hodgkin lymphoma cells. Currently in Phase II development, this therapy represents a promising option for patients with relapsed or refractory disease and reflects the growing interest in personalized cell-based treatment approaches.
- GEN3017 – Genmab
GEN3017 is a bispecific monoclonal antibody targeting both CD30 and CD3, designed to redirect T cells toward malignant Hodgkin lymphoma cells. The therapy is currently being evaluated in Phase I/II clinical studies and represents a novel mechanism of action within the evolving treatment landscape.
Find out more about Hodgkin’s Lymphoma therapies, clinical trials, and emerging treatment opportunities in the full market report.
Hodgkin’s Lymphoma: Therapeutic Assessment
The therapeutic assessment section provides detailed insights into marketed and emerging therapies based on several analytical parameters:
Major Players
Several pharmaceutical and biotechnology companies are actively developing therapies for Hodgkin’s Lymphoma. Key companies include Merck, Bristol Myers Squibb, Takeda, Pfizer, Genmab, ADC Therapeutics, Seagen, and BeiGene.
Phases
The development pipeline includes approved therapies as well as candidates in Phase III, Phase II, and Phase I/II stages, demonstrating ongoing innovation across immunotherapy, bispecific antibodies, CAR-T therapies, and targeted treatments.
Route of Administration
Pipeline products are being developed across multiple administration routes, including:
- Intravenous (IV)
- Oral
Molecule Type
The Hodgkin’s Lymphoma pipeline includes a diverse range of molecule types, including:
- Monoclonal antibodies
- Bispecific antibodies
- CAR-T cell therapies
- Small molecules
- Immune checkpoint inhibitors
Product Type
The market includes monotherapies as well as combination regimens integrating chemotherapy, immunotherapy, and targeted therapies to improve treatment outcomes and patient survival.
Hodgkin’s Lymphoma Market Outlook
The Hodgkin’s Lymphoma market is expected to experience substantial growth through 2036, driven by increasing disease awareness, improved diagnostic capabilities, expanding use of immunotherapies, and strong clinical research activity. Rising adoption of premium therapies such as PD-1 inhibitors and antibody-drug conjugates is reshaping treatment paradigms, particularly in relapsed or refractory disease settings.
The United States currently accounts for the largest market share across the 7MM and is expected to maintain its leadership position throughout the forecast period. In 2024, approximately 8,570 new Hodgkin lymphoma cases were estimated in the US, including 4,630 males and 3,940 females. Germany is projected to hold the largest market share among European countries.
The treatment landscape continues to evolve with established therapies such as KEYTRUDA, OPDIVO, and ADCETRIS, alongside promising emerging agents including TEVIMBRA and Favezelimab/Pembrolizumab. Personalized treatment strategies utilizing PET2 imaging, biomarker-guided approaches, and combination regimens are expected to further improve patient outcomes and market growth.
Key Market Highlights
- The Hodgkin’s Lymphoma market is projected to grow at a significant CAGR during 2026–2036.
- The US accounted for the largest market share among the 7MM.
- More than 80% of Hodgkin lymphoma patients can be cured with current treatment approaches.
- The disease shows peak incidence among young adults and older populations.
- KEYTRUDA, OPDIVO, and ADCETRIS remain key marketed therapies.
- TEVIMBRA, Favezelimab/Pembrolizumab, GEN3017, and CD30 CAR-T therapies represent promising pipeline candidates.
- Increasing regulatory support, orphan drug incentives, and accelerated approval pathways continue to encourage innovation.
- Strong clinical trial activity is accelerating the development of next-generation therapies.
Request a free sample report today to gain comprehensive insights into the Hodgkin’s Lymphoma market, competitive landscape, and future growth opportunities.
Conclusion
The Hodgkin’s Lymphoma market is entering a transformative phase driven by advances in immunotherapy, targeted treatments, cellular therapies, and precision medicine approaches. Despite already high cure rates, ongoing research continues to improve long-term outcomes, reduce treatment-related toxicity, and address unmet needs in relapsed and refractory patients. With strong epidemiological growth, an active development pipeline, increasing regulatory support, and continued innovation from leading pharmaceutical companies, the Hodgkin’s Lymphoma market is expected to witness substantial expansion through 2036. The introduction of novel therapies and optimized treatment combinations is poised to further enhance patient care and create significant commercial opportunities across the global market.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
